Advanced search
Publication Cover
Expert Review of Anti-infective Therapy Volume 10, 2012 - Issue 8
Submit an article Journal homepage
134
Views
10
CrossRef citations to date
0
Altmetric
Clinical Trial Report

Telavancin for the treatment of hospital-acquired pneumonia: findings from the ATTAIN studies

Esteban C Nannini Section of Infectious Diseases, Faculty of Medicine, Universidad Nacional de Rosario, Rosario, Argentina. [email protected]; Section of Infectious Diseases, Faculty of Medicine, Universidad Nacional de Rosario, Rosario, Argentina. [email protected]
,
G Ralph Corey Duke Clinical Research Institute, Durham, NC, USA; Division of Infectious Diseases, DukeUniversity Medical Center, Durham, NC, USA; Duke Clinical Research Institute, Durham, NC, USA; Division of Infectious Diseases, DukeUniversity Medical Center, Durham, NC, USA
&
Martin E Stryjewski Duke Clinical Research Institute, Durham, NC, USA; Department of Medicine and Division of Infectious Diseases, Centro de Educación Médica e Investigaciones Clínicas “Norberto Quirno”, BuenosAires, Argentina; Duke Clinical Research Institute, Durham, NC, USA; Department of Medicine and Division of Infectious Diseases, Centro de Educación Médica e Investigaciones Clínicas “Norberto Quirno”, BuenosAires, Argentina
Pages 847-854 | Published online: 10 Jan 2014

References

  • Morrison AJ Jr Kaiser DL, Wenzel RP. A measurement of the efficacy of nosocomial infection control using the 95 per cent confidence interval for infection rates. Am.J. Epidemiol. 126(2), 292–297 (1987).
  • Wenzel RP, Edmond MB. The impact of hospital-acquired bloodstream infections. Emerging Infect. Dis. 7(2), 174–177 (2001).
  • Tablan OC, Anderson LJ, Besser R, Bridges C, Hajjeh R; CDC; Healthcare Infection Control Practices Advisory Committee. Guidelines for preventing health-care–associated pneumonia, 2003: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee. MMWR Recomm. Rep. 53(RR-3), 1–36 (2004).
  • Torres A, Aznar R, Gatell JM et al. Incidence, risk, and prognosis factors of nosocomial pneumonia in mechanically ventilated patients. Am. Rev. Respir. Dis. 142(3), 523–528 (1990).
  • Chastre J, Fagon JY. Ventilator-associated pneumonia. Am. J. Respir. Crit. Care Med. 165(7), 867–903 (2002).
  • Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit. Care Med. 27(5), 887–892 (1999).
  • Safdar N, Dezfulian C, Collard HR, Saint S. Clinical and economic consequences of ventilator-associated pneumonia: a systematic review. Crit. Care Med. 33(10), 2184–2193 (2005).
  • Jones RN. Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin. Infect. Dis. 51(Suppl. 1), S81–S87 (2010).
  • Liu C, Bayer A, Cosgrove SE et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin.Infect. Dis. 52(3), 285–292 (2011).
  • Soriano A, Marco F, Martínez JA et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. 46(2), 193–200 (2008).
  • Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J. Clin. Microbiol. 42(6), 2398–2402 (2004).
  • Moise PA, Sakoulas G, Forrest A, Schentag JJ. Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother. 51(7), 2582–2586 (2007).
  • Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch. Intern. Med. 166(19), 2138–2144 (2006).
  • Lamer C, de Beco V, Soler P et al. Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob. Agents Chemother. 37(2), 281–286 (1993).
  • Jeffres MN, Isakow W, Doherty JA et al. Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest 130(4), 947–955 (2006).
  • Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob. Agents Chemother. 52(4), 1330–1336 (2008).
  • Boselli E, Breilh D, Rimmelé T et al. Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia. Crit. Care Med. 33(7), 1529–1533 (2005).
  • Wunderink RG, Cammarata SK, Oliphant TH, Kollef MH; Linezolid Nosocomial Pneumonia Study Group. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin. Ther. 25(3), 980–992 (2003).
  • Kalil AC, Murthy MH, Hermsen ED, Neto FK, Sun J, Rupp ME. Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: a systematic review and meta-analysis. Crit. Care Med. 38(9), 1802–1808 (2010).
  • Karvouniaris M, Makris D, Karabekos D, Zakynthinos E. Nosocomial MRSA pneumonia: data from recent clinical trials. Rev. Recent Clin. Trials 6(3), 235–240 (2011).
  • Wunderink RG, Niederman MS, Kollef MH et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin. Infect. Dis. 54(5), 621–629 (2012).
  • Gould FK. Linezolid: safety and efficacy inspecial populations. J. Antimicrob. Chemother. 66(Suppl. 4), iv3–iv6 (2011).
  • Reyes N, Skinner R, Kaniga K et al. Efficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49(10), 4344–4346 (2005).
  • Crandon JL, Kuti JL, Nicolau DP. Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model. Antimicrob. Agents Chemother. 54(12), 5115–5119 (2010).
  • Rubinstein E, Lalani T, Corey GR et al.; ATTAIN Study Group. Telavancin versus vancomycin for hospital-acquired pneumonia due to Gram-positive pathogens. Clin. Infect. Dis. 52(1), 31–40 (2011).
  • Van Bambeke F. Glycopeptides in clinical development: pharmacological profile and clinical perspectives. Curr. Opin. Pharmacol. 4(5), 471–478 (2004).
  • Leadbetter MR, Adams SM, Bazzini B et al. Hydrophobic vancomycin derivatives with improved ADME properties: discovery of telavancin (TD-6424). J.Antibiot. 57(5), 326–336 (2004).
  • Higgins DL, Chang R, Debabov DV et al. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49(3), 1127–1134 (2005).
  • Silverman JA, Perlmutter NG, Shapiro HM. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob. Agents Chemother. 47(8), 2538–2544 (2003).
  • Lunde CS, Hartouni SR, Janc JW, Mammen M, Humphrey PP, Benton BM. Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipidII. Antimicrob. Agents Chemother. 53(8), 3375–3383 (2009).
  • Pace JL, Krause K, Johnston D et al. Invitro activity of TD-6424 against Staphylococcus aureus. Antimicrob. Agents Chemother. 47(11), 3602–3604 (2003).
  • Leuthner KD, Cheung CM, Rybak MJ. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 58(2), 338–343 (2006).
  • Barcia-Macay M, Lemaire S, Mingeot-Leclercq MP, Tulkens PM, Van Bambeke F. Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 58(6), 1177–1184 (2006).
  • Sahm D, Draghi D, Benton B, Jones M, Krause K, Thornsberry C. Europe surveillance initiative profiling the anti-enterococcal activity of telavancin by specimen source from 2004 to 2005. Presented at: 17th European Congress of Clinical Microbiology and Infectious Diseases. Munich, Germany, 31 March–4 April (2007).
  • Hegde SS, Skinner R, Lewis SR, Krause KM, Blais J, Benton BM. Activity of telavancin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in vitro and in an in vivo mouse model of bacteraemia. J. Antimicrob. Chemother. 65(4), 725–728 (2010).
  • Hegde SS, Reyes N, Wiens T et al. Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against Gram-positive bacteria. Antimicrob. Agents Chemother. 48(8), 3043–3050 (2004).
  • Odenholt I, Löwdin E, Cars O. Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model. Antimicrob. Agents Chemother. 51(9), 3311–3316 (2007).
  • King A, Phillips I, Kaniga K. Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria. J.Antimicrob. Chemother. 53(5), 797–803 (2004).
  • Mendes RE, Moet GJ, Janechek MJ, Jones RN. In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates. Antimicrob. Agents Chemother. 54(6), 2704–2706 (2010).
  • Saravolatz LD, Pawlak J, Johnson LB. Comparative activity of telavancin against isolates of community-associated methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 60(2), 406–409 (2007).
  • Pfaller MA, Mendes RE, Sader HS, Jones RN. Telavancin activity against Gram-positive bacteria isolated from respiratory tract specimens of patients with nosocomial pneumonia. J. Antimicrob. Chemother. 65(11), 2396–2404 (2010).
  • Mendes RE, Sader HS, Farrell DJ, Jones RN. Telavancin activity tested against a contemporary collection of Gram-positive pathogens from USA Hospitals (2007–2009). Diagn. Microbiol. Infect. Dis. 72(1), 113–117 (2012).
  • Kosowska-Shick K, Clark C, Pankuch GA et al. Activity of telavancin against staphylococci and enterococci determined by MIC and resistance selection studies. Antimicrob. Agents Chemother. 53(10), 4217–4224 (2009).
  • Stryjewski ME, O’Riordan WD, Lau WK et al.; FAST Investigator Group. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to Gram-positive bacteria. Clin. Infect. Dis. 40(11), 1601–1607 (2005).
  • Stryjewski ME, Chu VH, O’Riordan WD et al.; FAST 2 Investigator Group. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by Gram-positive bacteria: FAST 2 study. Antimicrob. Agents Chemother. 50(3), 862–867 (2006).
  • Vibativ® (telavancin), package insert. Astellas Pharma, Inc., Deerfield, IL, USA (2009).
  • Shaw JP, Seroogy J, Kaniga K, Higgins DL, Kitt M, Barriere S. Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob. Agents Chemother. 49(1), 195–201 (2005).
  • Nannini EC, Stryjewski ME. A new lipoglycopeptide: telavancin. Expert Opin. Pharmacother. 9(12), 2197–2207 (2008).
  • Sun HK, Duchin K, Nightingale CH, Shaw JP, Seroogy J, Nicolau DP. Tissue penetration of telavancin after intravenous administration in healthy subjects. Antimicrob. Agents Chemother. 50(2), 788–790 (2006).
  • Gotfried MH, Shaw JP, Benton BM et al. Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics. Antimicrob. Agents Chemother. 52(1), 92–97 (2008).
  • Wong SL, Shaw JP, Gotfried MH, Barriere SL, Kitt MM, Goldberg MR. Compartmental analysis of telavancin penetration into epithelial lining fluid and alveolar macrophages. Presented at: 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco, CA, USA, 27–30 Septemeber (2006).
  • Lodise TP Jr Gotfried M, Barriere S, Drusano GL. Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation. Antimicrob. Agents Chemother. 52(7), 2300–2304 (2008).
  • Lodise TP, Drusano GL, Butterfield JM, Scoville J, Gotfried M, Rodvold KA. Penetration of vancomycin into epithelial lining fluid in healthy volunteers. Antimicrob. Agents Chemother. 55(12), 5507–5511 (2011).
  • Goldberg MR, Wong SL, Shaw JP, Kitt MM, Barriere SL. Lack of effect of moderate hepatic impairment on the pharmacokinetics of telavancin. Pharmacotherapy 30(1), 35–42 (2010).
  • Wong SL, Goldberg MR, Ballow CH, Kitt MM, Barriere SL. Effect of telavancin on the pharmacokinetics of the cytochrome P450 3A probe substrate midazolam: a randomized, double-blind, crossover study in healthy subjects. Pharmacotherapy 30(2), 136–143 (2010).
  • Stryjewski M, Corey GR, Barriere S, Genter FC, Rubinstein E. Vancomycin serum trough levels and outcomes in patients with hospital-acquired pneumonia due to Staphylococcus aureus: the ATTAIN study (abstract # O36). Presented at: 20th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Vienna, Austria, 10–13 April (2010).
  • Stryjewski ME, Graham DR, Wilson SE et al.; Assessment of Telavancin in Complicated Skin and Skin-Structure Infections Study. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by Gram-positive organisms. Clin. Infect. Dis. 46(11), 1683–1693 (2008).
  • Barriere S, Genter F, Spencer E, Kitt M, Hoelscher D, Morganroth J. Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects. J. Clin. Pharmacol. 44(7), 689–695 (2004).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.